Previous 10 | Next 10 |
home / stock / ucbjy / ucbjy news
UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results - Positive topline results show the Phase 3 RAISE (NCT04115293) zilucoplan trial met primary and all key secondary endpoints in adults with generalized myasthenia gravis - The results show...
Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study - The BE COMPLETE study evaluated bimekizumab in adults with active psoriatic arthritis who were inadequate responders or intolerant to anti-TNF treatment - BE COMPLETE is the second positi...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Zogenix (NASDAQ: ZGNX ) stock is skyrocketing on Wednesday following news that UCB (OTCMKTS: UCBJY ) intends to acquire the company in a $1.9 billion deal. Source: Shutterstock.com The deal between the t...
UCB to acquire Zogenix - Transaction broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy, complementing existing medicines and expanding clinical development pipeline of epilepsy and rare dise...
Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study - The BE MOBILE 1 study met the primary and all ranked secondary endpoints, showing that bimekizumab improved outcomes in patients with active non-radiographic axial spondyloarthr...
Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial - BE MOBILE 2 is a Phase 3 study evaluating the efficacy and safety of bimekizumab in the treatment of patients with active ankylosing spondylitis - The trial met the primary endpoint and all r...
UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021, reinforcing long-standing commitment to advancing epilepsy treatment and care - 17 scientific presentations illustrate and reinforce UCB's commitment to improving the lives of people living with e...
UCB Announces Global Partnership To Bring Disease-Modifying Therapies To People Living With Parkinson's Disease -- UCB to partner with Novartis on development of UCB0599 with an opt-in to develop UCB7853, two innovative and potentially disease-modifying investigational assets in...
Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms -- The BE OPTIMAL study met the primary endpoint and all ranked secondary endpoints with statistical significance -- The study used t...
UCB Showcases Key Rheumatology Data at ACR Convergence 2021 -- Eleven abstracts across UCB's rheumatology portfolio, including investigational bimekizumab and CIMZIA® (certolizumab pegol), underscore UCB's dedication to rheumatology -- Long-term three-year data from Pha...
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
UCB partners with Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi in their heartfelt musical about living with epilepsy: It's All Your Fault, Tyler Price! PR Newswire Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi announce the fu...
FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia PR Newswire FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels PR Newswire Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can ...